We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

71 hedge funds and large institutions have $26M invested in Applied Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

3% more funds holding

Funds holding: 6971 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 19

9.81% less ownership

Funds ownership: 56.91%47.1% (-9.8%)

61% less call options, than puts

Call options by funds: $22K | Put options by funds: $57K

80% less capital invested

Capital invested by funds: $133M → $26M (-$107M)

Holders
71
Holders Change
+2
Holders Change %
+2.9%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
19
Reduced
19
Closed
13
Calls
$22K
Puts
$57K
Net Calls
-$35K
Net Calls Change
-$636K

APLT Hedge Fund Activity: Q1 2022 in Review

71 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q1 2022, worth a combined $26M — down 80% from $133M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new APLT positions and 13 closed out — a net gain of 2 holders — while 19 added to existing stakes and 19 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $3.84M. The largest seller was OrbiMed, exiting entirely with an estimated $20.7M sold.

  • 71 institutional investors held Applied Therapeutics (APLT) as of Q1 2022, up from 69 in Q4 2021.
  • Funds reported $26M of Applied Therapeutics stock for Q1 2022, down 80% quarter-over-quarter.
  • 15 funds opened new Applied Therapeutics positions in Q1 2022 and 13 closed out, a net change of +2 holders.
  • The largest Applied Therapeutics buyer in Q1 2022 was Point72 Asset Management, an estimated $3.84M added.
  • The largest Applied Therapeutics seller in Q1 2022 was OrbiMed, an estimated $20.7M sold.

Based on aggregated 13F filings for Q1 2022.